|1.||Kim, Yong-Lim: 7 articles (07/2013 - 10/2003)|
|2.||Park, Sun-Hee: 6 articles (05/2013 - 10/2003)|
|3.||Crump, Michael: 4 articles (08/2015 - 01/2006)|
|4.||Kim, Chan-Duck: 4 articles (05/2013 - 02/2007)|
|5.||Wagner, A: 4 articles (12/2004 - 04/2002)|
|6.||Reinhardt, R: 4 articles (12/2004 - 04/2002)|
|7.||Manaenko, A: 4 articles (12/2004 - 04/2002)|
|8.||Chen, Bingshu E: 3 articles (08/2015 - 11/2014)|
|9.||Meyer, Ralph M: 3 articles (08/2015 - 11/2014)|
|10.||Hay, Annette E: 3 articles (08/2015 - 11/2014)|
03/17/2015 - "In this study, using historical copies of the British National Formulary and relevant contemporary publications, we have documented for each new cancer drug the year of introduction, therapeutic classification, initial indication, median duration of treatment and the cost of treatment at introduction relative to the then current UK GDP per capita. "
01/01/2014 - "In the present study, a multiple regression analysis was used to clarify the relationships between the lifespan and socio-economic conditions, such as the GDP, GiNi index, age-adjusted mortality from cancer, suicide rate and self-rated health in 27 European countries. "
04/01/2004 - "The phantom study revealed that LN model showed TNRa of 1.7 or greater by GDP count rate (cps) when background contained no FDG, but that they showed TNRa of 1.3 or less when the background contained 4% of the LN FDG activity per ml. The present study suggests that higher FDG count rate of tumors at 1-3 hr postinjection would be more suitable for the gamma-probe detection compared with lower count rate at 6-7 hr delayed scans with wide standard deviations."
04/01/2004 - "The patient study revealed that tumors showed constant TNRa (0.9-1.3) and TNRc (1.1-3.0) by GDP count rate, and that there was no tendency of an increase in TNRa with time. "
01/01/2004 - "The index of infectious burden in this study has been chosen to be poverty, i.e., low GDP, high infantile mortality, poor hygienic conditions, inaccessibility to modern medical infra-structures, etc. When estimates of observed cancer incidence is plotted against the GDP of 24 regions of the world, a trend line is obtained: low GDP (a proxy for high infectious burden) tends to be associated with low incidence of cancer whereas high GDP values herald higher cancer occurrences. "
|2.||Acquired Immunodeficiency Syndrome (AIDS)
11/01/2012 - "This study confirms that GDP is an effective and safe salvage regimen in relapsed or refractory AIDS-NHL, was associated with modest declines in CD4⁺ lymphocyte counts, and did not promote HIV-1 viral replication."
01/01/2002 - "The objective of this study was to estimate the burden of HIV/AIDS on GDP in the WHO African Region using a production function approach. "
05/01/1993 - "The 1956 Solow growth model is expanded to study the effects of the AIDS epidemic on the growth path of the economy and per capita GDP (gross domestic product). "
01/01/2014 - "The modeling results for the Asian countries indicates HIV/AIDS prevalence that has a hurtful effect on GDP per capita by reducing human capitals within countries over time. "
01/01/2014 - "The econometric effects concerned that HIV/AIDS plays an important role in the field of economic growths and it is measured as a change in real gross domestic product (GDP) per capita and human capitals. "
|3.||Non-Hodgkin Lymphoma (Lymphosarcoma)
08/06/2015 - "Six-hundred nineteen patients with relapsed/refractory aggressive non-Hodgkin lymphoma were randomized to GDP or DHAP; 87 patients (14%) had TRIL and 429 (69%) had DLBCL. "
11/01/2008 - "[Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases]."
11/01/2012 - "Study on effectiveness of gemcitabine, dexamethasone, and cisplatin (GDP) for relapsed or refractory AIDS-related non-Hodgkin's lymphoma."
12/01/2012 - "This study was conducted to evaluate the efficacy and safety of Rituximab, Gemcitabine, Cisplatin, and Dexamethasone (R-GDP) in relapsed or refractory aggressive B-Cell Non-Hodgkin's Lymphoma (NHL). "
11/01/2013 - "Regarding combination therapy, the GDP regimen consisting of gemcitabine, dexamethasone, and cisplatin was associated with response rates of 62-70% for relapsed or refractory Hodgkin lymphoma and 45-53% for relapsed or refractory non-Hodgkin lymphoma, thereby displaying comparable efficacy to existing salvage chemotherapy regimens. "
|4.||Body Weight (Weight, Body)
10/01/1985 - "In acute studies, the binding of GDP was significantly increased after 3, 24, and 48 hours of treatment with a single dose of 20 mg/kg of body weight. "
10/01/1994 - "Sixteen weeks exposure to short photoperiod resulted in large decreases in body weight and interscapular BAT mass that were accompanied by an increase in the thermogenic activity of BAT (estimated by mitochondrial GDP binding). "
06/01/1989 - "Chronic infusion of CRF into the IIIrd ventricle of obese rats resulted in a reduction of food intake and body weight gain but IBAT mitochondrial GDP binding was unaltered by the treatment. "
01/01/1988 - "When prenatally underfed rat pups were nursed by dams that were fed with the hypocaloric diet during lactation, neonatal body weight continued lower at the two mentioned days of life and the overall thermogenic capacity of brown fat (GDP binding/g body weight) was substantially depressed. "
01/01/1984 - "It is suggested that the decreased GDP binding is partly compensated for by an increase in the mitochondrial content of the brown adipose tissue of the ob/+ mice, thus normalizing the total thermogenic capacity and allowing the maintenance of lean body weight despite a slight expression of the obese gene in the thermogenic pathway."
|5.||Ovarian Neoplasms (Ovarian Cancer)
|1.||Guanosine Diphosphate (GDP)
|2.||Guanosine Triphosphate (GTP)
|10.||L-Lactate Dehydrogenase (Lactate Dehydrogenase)
|2.||Drug Therapy (Chemotherapy)
|4.||Stem Cell Transplantation
|5.||Prostheses and Implants (Prosthesis)